We are live on ! Find out more
PRVL

Prevail Therapeutics Inc. Common Stock
PRVL

Delisted

PRVL was delisted on the 21st of January, 2021.

Back to rankings

76 hedge funds and large institutions have $302M invested in Prevail Therapeutics Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 11

28% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 18

13% more funds holding

Funds holding: 67 → 76 (+9)

28% less capital invested

Capital invested by funds: $421M → $302M (-$119M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
76
Holders Change
+9
Holders Change %
+13.43%
% of All Funds
1.53%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
20
Increased
23
Reduced
18
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$16.6M
2
HighTower Advisors
HighTower Advisors
Illinois
+$15.2M
3
BlackRock
BlackRock
New York
+$7.5M
4
Morgan Stanley
Morgan Stanley
New York
+$3.66M
5
Bank of America
Bank of America
North Carolina
+$3.05M

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$15.3M
2
RCM
RA Capital Management
Massachusetts
-$7.77M
3
EC
EcoR1 Capital
California
-$5.47M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$4.35M
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$914K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$141M – – –
Citadel Advisors
2
Citadel Advisors
Florida
$24.6M +$16.6M +1,239,405 +106%
BlackRock
3
BlackRock
New York
$20.4M +$7.5M +559,017 +39%
RCM
4
RA Capital Management
Massachusetts
$19.5M -$7.77M -579,123 -23%
HighTower Advisors
5
HighTower Advisors
Illinois
$11.5M +$15.2M +1,130,000 New
BC
6
Boxer Capital
California
$11.4M – – –
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$10.9M -$4.35M -324,223 -23%
Vanguard Group
8
Vanguard Group
Pennsylvania
$7.8M +$496K +36,952 +5%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$6.87M -$902K -67,200 -9%
Morgan Stanley
10
Morgan Stanley
New York
$6.54M +$3.66M +273,002 +74%
Bank of America
11
Bank of America
North Carolina
$4.92M +$3.05M +227,246 +89%
WP
12
Woodline Partners
California
$3.92M +$756K +56,345 +17%
AG
13
Artal Group
Luxembourg
$3.08M -$902K -67,250 -18%
CI
14
Clal Insurance
Israel
$2.97M – – –
State Street
15
State Street
Massachusetts
$2.57M +$103K +7,661 +3%
Federated Hermes
16
Federated Hermes
Pennsylvania
$1.94M +$168K +12,487 +7%
OFM
17
Omega Fund Management
Massachusetts
$1.91M – – –
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1.74M +$90K +6,705 +4%
Northern Trust
19
Northern Trust
Illinois
$1.61M +$294K +21,881 +16%
Point72 Asset Management
20
Point72 Asset Management
Connecticut
$1.6M +$2.11M +157,335 New
QF
21
QVT Financial
New York
$1.36M – – –
Bank of New York Mellon
22
Bank of New York Mellon
New York
$1.32M -$914K -68,116 -34%
N
23
Nuveen
North Carolina
$1.03M +$506K +37,727 +59%
Renaissance Technologies
24
Renaissance Technologies
New York
$897K +$409K +30,500 +53%
DCM
25
DAFNA Capital Management
California
$764K – – –
1
2 3 4

PRVL Hedge Fund Activity: Q3 2020 in Review

76 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q3 2020, worth a combined $302M — down 28% from $421M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new PRVL positions and 11 closed out — a net gain of 9 holders — while 23 added to existing stakes and 18 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $16.6M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $15.3M sold.

  • 76 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q3 2020, up from 67 in Q2 2020.
  • Funds reported $302M of Prevail Therapeutics Inc. Common Stock stock for Q3 2020, down 28% quarter-over-quarter.
  • 20 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q3 2020 and 11 closed out, a net change of +9 holders.
  • The largest Prevail Therapeutics Inc. Common Stock buyer in Q3 2020 was Citadel Advisors, an estimated $16.6M added.
  • The largest Prevail Therapeutics Inc. Common Stock seller in Q3 2020 was Avidity Partners Management, an estimated $15.3M sold.

Based on aggregated 13F filings for Q3 2020.